Erschienen in:
Open Access
01.12.2020 | Review
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
verfasst von:
Alberto Ocaña, Eitan Amir, Atanasio Pandiella
Erschienen in:
Breast Cancer Research
|
Ausgabe 1/2020
Abstract
Background
There has been substantial interest in HER2 intratumoral heterogeneity as an explanation for the development of resistance to anti-HER2 therapies in breast cancer, particularly to trastuzumab emtansine (T-DM1).
Methods
Through a literature-based approach, we discuss mechanisms of resistance to HER2-targeting antibody-drug conjugates (ADCs) in breast cancer.
Results
We describe results from clinical studies reporting the effect of anti-HER2 strategies particularly ADCs and their mechanistic effect. We review biological findings underlying HER2 heterogeneity and its implication in the development of novel anti-HER2 drugs including new ADCs in clinical development like trastuzumab deruxtecan (DS-8201).
Conclusions
We suggest potential mechanisms to optimize these compounds and their future clinical implementation.